Guidance from the American College of Medical Genetics and Genomics expected to reduce impact of VUS in genetic testing

ASHG 2026

Oct 20, 2026
Presentation

Heidi L. Rehm, Chloe Mighton, Aya Abu-El-Haija, Vimla Aggarwal, Yassmine MN Akkari, Caroline Astbury, D. Hunter Best, Laura K. Conlin, Steven M. Harrison, Nan Jiang, Paul Kruszka, Dianalee McKnight, Tiffany T. Nguyen Dolphyn, Farid Barquet Ramos, Christie P. Thomas, Lora J. H. Bean

Abstract
Variants of uncertain significance (VUS) are a major challenge, reported in ~30% of symptomatic genetic tests. While some standards exist to guide VUS reporting, a systematic approach is lacking. To this end, an American College of Medical Genetics and Genomics working group was convened to develop guidance on germline VUS reporting for sequence and structural variants from any testing platform. Points to consider were developed based on existing policies, technical standards, professional practice, evidence from the literature, input from external experts, and results from a globally circulated survey. The working group concluded that VUS are recommended for return in symptomatic testing when related to the phenotype. VUS are not recommended for return when identified in asymptomatic individuals. Exceptions are permissible in specific, limited scenarios. In the guidance, laboratories are encouraged to adopt VUS subclasses and consider methods to bring attention to variants that most likely explain the patient’s phenotype, including VUS-high, and de-emphasize or omit VUS unlikely to be causal. Survey respondents (n=828) largely agreed with recommendations, with the majority selecting agree/strongly agree for almost all testing scenarios. With regards to strategies for de-emphasizing VUS less likely to explain the indication for testing, partitioning VUS and including VUS subclass terms on the report had the strongest support (>60% of respondents). Respondents predominantly felt that individuals undergoing testing should not be provided the option to opt out of having VUS reported. There was no consensus on whether these principles should apply to the research setting. Free text responses included implementation concerns (16%), result-specific considerations (13%), equity considerations (2%), jurisdictional differences (1.5%), and technology-specific considerations (0.9%). Survey responses informed the final document, soon to be published. This guidance fills a gap in professional practice, providing recommendations to balance potential benefits of reporting VUS with potential harms. Implementation of this guidance along with the forthcoming sequence variant classification standards are expected to reduce the rate of VUS on reports and help target physician follow-up to a much smaller subset of variants.